a88eb22f-2455-401a-a7a9-cf8e0bb85f1f - samples

NIAID Data Ecosystem2026-03-12 收录

乳腺癌新辅助化疗预测

转录组-代谢成像联合分析

数据链接：

https://www.omicsdi.org/dataset/ega/EGAD00001008141 数据链接链接失效反馈

官方服务：

资源简介：

Transcriptomic data for five patients with breast cancer undergoing neoadjuvant chemotherapy and hyperpolarised 13C-MRI for early response assessmentEGA dataset EGAD00001008141

创建时间：

2021-10-04

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

乳腺癌新辅助化疗预测

肿瘤免疫生物标志物

We report the ability of a gene expression signature to predict response to neoadjuvant chemotherapy in early breast cancer, and also describe transcriptomic changes during treatment Overall design: T

NIAID Data Ecosystem60

On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

乳腺癌新辅助化疗预测

治疗中生物标志物发现

Background: Neoadjuvant chemotherapy is increasingly being used to preoperatively shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes ass

NIAID Data Ecosystem50

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis

癌症生物标志物

乳腺癌新辅助化疗预测

IntroductionSPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast ca

Figshare2016-01-18 更新40

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab on NSABP B-40. Homo sapiens

乳腺癌新辅助化疗预测

牛基因组关联研究

"Source of Patients Patients entered into this study were from the NSABP B-40 trial in which patients were randomized to one of three chemotherapy regimens with one-half of the patients also randomize

NIAID Data Ecosystem50

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

乳腺癌新辅助化疗预测

基因组预测模型验证

PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-bas

NIAID Data Ecosystem40

a88eb22f-2455-401a-a7a9-cf8e0bb85f1f - samples

资源简介：

相关数据集